about
Prediction and preliminary validation of oncogene regulation by miRNAsProteomic profiling of Myc-associated proteinsGadd45 stress sensors in malignancy and leukemiaIntrinsically disordered proteins are potential drug targetsHypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1Crystal Structure of the Minimalist Max-E47 Protein ChimeraProline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage responseMax-E47, a designed minimalist protein that targets the E-box DNA site in vivo and in vitro.Protein Cysteines Map to Functional Networks According to Steady-state Level of Oxidation.Indirect genomic effects on survival from gene expression dataRNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.Reengineering natural design by rational design and in vivo library selection: the HLH subdomain in bHLHZ proteins is a unique requirement for DNA-binding functionMyc is required for activation of the ATM-dependent checkpoints in response to DNA damageCardiovascular responses to cold exposureThe role of viral and bacterial pathogens in gastrointestinal cancer.Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells.Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entrySmall molecules targeting c-Myc oncogene: promising anti-cancer therapeuticsp300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaNanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancerMYCbase: a database of functional sites and biochemical properties of Myc in both normal and cancer cells.Delivery of intracellular-acting biologics in pro-apoptotic therapies.Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression.Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.Estrogenic or antiestrogenic therapies for multiple myeloma?Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.Specifically targeted gene therapy for small-cell lung cancer.3D tumour models: novel in vitro approaches to cancer studies.Potential in vivo roles of nucleic acid triple-helices.G-quadruplexes as potential therapeutic targets for embryonal tumors.Synthetic cajanin stilbene acid derivatives inhibit c-MYC in breast cancer cells.Myc: the beauty and the beast.Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells.Over-expression of c-Myc oncoprotein in oral squamous cell carcinoma in the South Indian population.External Qi of Yan Xin Qigong induces cell death and gene expression alterations promoting apoptosis and inhibiting proliferation, migration and glucose metabolism in small-cell lung cancer cells.Keratinocyte transcriptional regulation of the human c-Myc promoter occurs via a novel Lef/Tcf binding element distinct from neoplastic cells.
P2860
Q21262991-87659C15-BDAF-44E6-B93C-1379A8E06745Q24315890-5E7801BC-FE1B-4E2C-90D1-92D2C664D3F4Q24600698-8847AEFA-B2FF-4523-8712-A4E7BBC99328Q24633854-E04D6F6B-13DD-4F3A-A5B7-BC015C86334CQ24681460-EE5E19A1-4CA7-44A9-8FE5-8BC36F6EED9DQ27677836-0F735532-319A-46A3-AED5-FF3800A84246Q28239216-0AFFEECC-23ED-4881-814D-9E7490C75995Q30377167-FE366799-AAC5-4C76-B5FA-8B602AA0EC57Q30416903-E170920A-EFDB-48DC-AE6F-6E29CDC6CED7Q31150308-0B31AB97-D34F-481C-8EF5-3FBFDF80DC21Q33398834-065E8792-19E8-405D-A2DB-430B605F4898Q33525222-62E32123-0A05-47EC-8927-27B18759A664Q33527429-45EA3BDA-B7F9-4394-8F3F-528E4D65A77EQ33680767-F33C993F-D565-4CE0-9149-182FE030E91DQ33791751-BAD52073-D4C1-4CCA-9739-949E98B05D32Q33888111-F7E3B144-47B2-4841-9BDE-BF1B4B0C13C7Q33979793-0F678AF8-23DD-420A-A765-F7650BAEEEF1Q35103979-08097127-2FF2-419B-A5B7-A6E193FFD442Q35131676-6D71BA7E-5C32-4C5B-82AD-A31E540304C3Q35353405-372D7F40-146F-400F-A053-7F14AD9C3904Q35640069-7BE6B119-A903-42E9-A511-371870E6C64EQ35797583-C8DE0534-2DC8-43E3-BC89-F849CD8BD0BEQ36356958-E4EBF9C0-8F84-4E4D-8275-26685B812C1CQ36358393-4249B346-441A-4501-BBC6-55550D1B05EBQ36588920-46A3F2B3-23D3-4619-B1A0-D71ECA5A02A9Q36671809-DBE845E8-50FE-45C8-AB8A-69629FBA7F80Q36759171-26A57034-5340-442D-8AB8-9A6FECECFC4BQ36948728-1FF5C8DE-D3AC-4EF5-A089-AA3BC98085CEQ37007328-69ED81A1-4B62-4F45-A131-368A5D941A3CQ37257626-BB78C21C-D795-4C71-94E8-9D60E10A5AE0Q37449030-9DEE46B0-6B1B-4299-9E5B-CA12FDAB9A40Q37866146-38729E73-6C1B-4AAF-B7DE-07861E452493Q37869778-52D62388-39D6-447D-9195-C63B85939AF4Q38154988-F281D422-0618-4543-947F-A828DD933CA6Q38300836-97F690D0-4BAF-441E-BC63-01B299A1D38BQ38568550-E3DAC3D9-B095-4B01-80A6-40240951589CQ38734062-AC8AFBF5-C5A3-4EE6-8F55-E6F9BAA9AF76Q39369837-ABA6219E-3E80-4B6F-A87C-BF2BAEEE97C8Q39429668-9F45208C-35D7-4C18-A41A-01952126D243Q40139624-68D44D99-D982-493E-8D98-0238CA932D61
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cancer therapeutics: targeting the dark side of Myc.
@ast
Cancer therapeutics: targeting the dark side of Myc.
@en
type
label
Cancer therapeutics: targeting the dark side of Myc.
@ast
Cancer therapeutics: targeting the dark side of Myc.
@en
prefLabel
Cancer therapeutics: targeting the dark side of Myc.
@ast
Cancer therapeutics: targeting the dark side of Myc.
@en
P2093
P1476
Cancer therapeutics: targeting the dark side of Myc.
@en
P2093
Linda Z Penn
Romina Ponzielli
Sigal Katz
P304
P356
10.1016/J.EJCA.2005.08.017
P577
2005-10-20T00:00:00Z